BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38424218)

  • 21. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
    Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
    Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
    Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
    Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
    Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
    Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
    Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
    BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Ogino Y; Sato A; Uchiumi F; Tanuma SI
    Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoring NAD
    Katayoshi T; Nakajo T; Tsuji-Naito K
    J Photochem Photobiol B; 2021 Aug; 221():112238. PubMed ID: 34130091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
    Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W; Baloglu E; Li J; Dyson G; Xue Y; El-Rayes B; Azmi AS
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
    Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
    Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
    Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
    [No Abstract]   [Full Text] [Related]  

  • 39. BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
    Li D; Chen NN; Cao JM; Sun WP; Zhou YM; Li CY; Wang XX
    Cell Cycle; 2014; 13(16):2564-71. PubMed ID: 25486197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.